Bayer Navigates a Political and Legal Minefield as Pipeline Progress Offers a Lifeline
Published on 06/25/2026 at 12:05 | Redaktion boerse-global.de
Bayer’s stock has defied the gravity of two looming threats that would rattle most German blue chips. The shares closed at €39.88 yesterday, up nearly 52% over the past twelve months and well above their 200-day moving average. That resilience is being tested from two directions: a newly launched US trade investigation into German drug pricing and a Supreme Court ruling on the glyphosate case Durnell that could land any day now. The company’s pipeline, however, has been throwing out positive signals that help explain why investors are not running for the exits.
The probe by the Office of the US Trade Representative, led by Jamieson Greer, kicks off its public comment period today, 25 June 2026. Washington’s grievance centres on a German bill that would impose an additional mandatory rebate on patented medicines, starting at 3.5% in early 2027 and rising to 20% by 2030. The US argues that American patients are effectively subsidising German R&D while German price controls keep domestic costs low. If the investigation leads to retaliation, tariffs on German pharmaceutical products could be introduced in two waves: the first set on 31 July 2026 and a second batch at the end of September. Even if a manufacturer shifts production to the US, a 20% tariff would apply, climbing to 100% after four years. The US has pointed to a parallel deal with the UK that guarantees British makers tariff?free access until early 2029, making the German industry’s position look especially exposed.
Meanwhile, Bayer is waiting on a verdict that could either lift a mountain of legal liability or keep the litigation mill grinding. The Supreme Court is expected to rule on Durnell by the end of this week. At stake is whether state law can override a safety clearance issued by the federal Environmental Protection Agency. A win for Bayer would effectively end roughly 65,000 outstanding claims; a loss would keep the wave rolling. The company has already budgeted legal expenses of around €5 billion for the current year, and the free cash flow is expected to dive into negative territory by as much as €2.5 billion. Net financial debt stood at €32.5 billion at the end of March, a burden that CFO Judith Hartmann is trying to manage alongside this year’s litigation cash outflow.
Should investors sell immediately? Or is it worth buying Bayer?
On the operational front, however, there are meaningful bright spots. The US Food and Drug Administration cleared Bayer’s new MRI contrast agent Ambelvist in mid?June. The drug requires just 0.04 mmol of gadolinium per kilogram of body weight – about 60% less than conventional agents – and is used to visualise lesions in the central nervous system. It already has approval in Japan. In addition, Bayer struck a deal in June to acquire Perfuse Therapeutics for an initial $300 million, securing rights to the PER?001 implant for eye diseases. Milestone payments could add up to $2.45 billion if development succeeds. The anticoagulant Asundexian has also been granted an accelerated review by the FDA, adding further promise to the pipeline.
The timing of these regulatory wins is crucial. The trade investigation’s public hearing is set for 22 September, and written submissions are due by 10 August. In the meantime, the stock has shrugged off the uncertainty. At €40.05, it has cleared its 50?day average of €37.68 and sits about 20% below its 52?week high near €50. Whether that gap narrows depends heavily on the Supreme Court’s pen. A favourable ruling would slash the litigation overhang and free up cash flow; an adverse one could trigger an immediate re?pricing of risk. With tariffs set to bite in late July, the next few weeks will tell whether Bayer’s pipeline momentum can keep the share price out of the crosshairs.
Ad
Bayer Stock: New Analysis - 25 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
